ClinicalTrials.gg
CompletedNCT00002412Updated Jun 24, 2005

A Study of MKC-442 in Combination With Other Anti-HIV Drugs

A Phase 2 interventional study of Emivirine and Hydroxyurea in HIV Infections, sponsored by Triangle Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Triangle Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing hydroxyurea in HIV Infections — none open to participants now, none under way, none of them phase 3. Hydroxyurea · HIV Infections.

Phase 2
6 of 13
none open now
Registered
1st of 13
by date
Lead sponsor
1 of 13
Triangle Pharmaceuticals

Among the 13 studies testing hydroxyurea in HIV Infections, this one is one of 6 in phase 2, and was the 1st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 13 studies testing hydroxyurea in HIV Infections is open now. The open studies under HIV Infections, anywhere →

Where they have run

About hydroxyurea

Hydroxyurea: first FDA approval 1967 (DROXIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing hydroxyurea in HIV Infections as a file.
02

Study summary

The purpose of this study is to see if it is safe and effective to give MKC-442 plus stavudine (d4T) plus didanosine (ddI) plus hydroxyurea.

Read the detailed description

Patients are randomized to receive either MKC-442 or placebo, along with stavudine(d4T), didanosine(ddI), and hydroxyurea. Patients will be treated and followed for 48 weeks.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • Didanosine
  • Drug Therapy, Combination
  • Stavudine
  • Hydroxyurea
  • Reverse Transcriptase Inhibitors
  • Anti-HIV Agents
  • Viral Load
  • MKC 442
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Concurrent Medication:

Allowed:

  • Based on medical history, medical condition, prior use of antiretroviral drugs, and genotypic analysis of the predominant strain of -1 isolated from the plasma, administration of a combination of two or more available antiretroviral agents by prescription may be given with MKC-442.

Patient must have:

  • HIV infection with HIV-1 RNA greater than or equal to 5,000 by Roche Amplicor method within 30 days of entry.
  • A failed protease inhibitor-containing regimen.
  • Negative serum beta human chorionic gonadotropin test within 30 days of entry.

Prior Medication:

Allowed:

  • Prior nucleoside reverse transcriptase and protease inhibitors.
  • Cytotoxic chemotherapy more than 30 days prior to entry.

Exclusion criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • Malabsorption or severe chronic diarrhea within 30 days prior to entry, or inability to consume adequate oral intake because of chronic nausea, emesis, or abdominal or esophageal discomfort.
  • Inadequately controlled seizure disorder.
  • Known intolerance to stavudine, didanosine, and/or hydroxyurea.
  • Acute and medical event within 30 days of screening.
  • Any clinical or laboratory abnormality greater than Grade 3 toxicity, with the exception of laboratory values given.

Concurrent Treatment:

Excluded:

  • Any experimental antiretroviral therapy or immunomodulators directed against -1, e.g., IL-4, cyclosporine at doses greater than 40 mg/day.

Prior Medication:

Excluded:

  • Non-nucleoside reverse transcriptase inhibitor therapy.

Prior Treatment:

Excluded:

  • Radiation therapy within 30 days of entry except to a local lesion.
  • Transfusion of blood or blood products within 21 days of screening.
  • Cytotoxic therapy within 3 months of study entry.

Risk Behavior:

Excluded:

Active substance abuse that may interfere with compliance or protocol evaluations.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Masking
Double

Interventions

06

Study locations

1 site
  • Dr Robert Wallace
    St. Petersburg, Florida 33713, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00002412
Lead sponsor
Triangle Pharmaceuticals
First posted
Aug 31, 2001
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 1999. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Hydroxyurea · Stavudine · Didanosine

Start the discussion